SCHEMBL5864307

SCHEMBL5864307

CCNC(=O)C1(CCCN2CCN(c3ccc4c(c3)C(=O)N(Cc3cccc(F)c3)C4)CC2)c2ccccc2Oc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
HTR7 P34969 3/20 0.39
DRD2 P14416 7/20 0.38
DRD3 P35462 6/20 0.38
DRD5 P21918 3/20 0.38
ACACB O00763 1/20 0.37
HTR1A P08908 3/20 0.36
ATM Q13315 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTR2A P28223 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
LIPG Q9Y5X9 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864053 0.98 HTR7 (0.42) LMNAHTR7DRD2DRD3DRD5
SCHEMBL5863715 0.94 LMNA (0.40) LMNAHTR7DRD2DRD3HTR1A
SCHEMBL5864047 0.93 LMNA (0.42) LMNAHTR7DRD2DRD3DRD5
SCHEMBL5863743 0.93 DRD2 (0.41) HTR7DRD2DRD3DRD5ACACB
SCHEMBL5864352 0.92 HTR7 (0.42) LMNAHTR7DRD2DRD3HTR1A
SCHEMBL5864195 0.92 LMNA (0.43) LMNAHTR7DRD2DRD3DRD5
SCHEMBL5863867 0.92 DRD3 (0.40) LMNAHTR7DRD2DRD3DRD5
SCHEMBL5864349 0.92 HTR7 (0.42) HTR7DRD2DRD3DRD5HTR1A
SCHEMBL5863868 0.91 HTR7 (0.44) LMNAHTR7DRD2DRD3DRD5
SCHEMBL5863918 0.91 DRD3 (0.42) HTR7DRD2DRD3DRD5ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC LMNA 508/4885HTR7 1820/4885DRD2 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.